No specific information from available sources identifies other drugs combined with ruxolitinib in Apotex's formulation. Apotex develops a generic version of ruxolitinib (the active ingredient in Jakafi), approved as monotherapy tablets for conditions like myelofibrosis and polycythemia vera, without fixed-dose combinations listed in regulatory filings or patent data.[1]
What is Apotex's ruxolitinib product?
Apotex received FDA tentative approval in 2023 for ruxolitinib phosphate tablets (5 mg, 10 mg, 15 mg, 20 mg, 25 mg), matching Incyte's Jakafi strengths. It is formulated as single-ingredient tablets, not combined with other APIs.[1][2]
Common ruxolitinib combinations in other products
Ruxolitinib appears in combinations outside Apotex's portfolio:
- Ruxolitinib + enasidenib: In clinical trials for acute myeloid leukemia (AML), but not commercialized.[3]
No Apotex-branded combo products exist per DrugPatentWatch and FDA Orange Book data.[1]
When can Apotex launch its generic?
Apotex's version faces Jakafi patent challenges, with key patents expiring in 2028. Full approval is blocked until then, pending Paragraph IV litigation outcomes.[1]
Alternatives to ruxolitinib combos
Physicians often pair ruxolitinib off-label with:
- Steroids (e.g., prednisone) for graft-versus-host disease.
- Azacitidine for myelodysplastic syndromes.
These are not fixed formulations.[3]
[1]: DrugPatentWatch.com - Ruxolitinib patents and generics
[2]: FDA Tentative Approval List
[3]: ClinicalTrials.gov - Ruxolitinib combinations